AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sign up Log in

Xspray Pharma Share Issue/Capital Change 2020

Oct 30, 2020

3129_rns_2020-10-30_349be2ba-cbeb-4ce5-a48d-011b3547747c.pdf

Share Issue/Capital Change

Open in viewer

Opens in your device viewer

Number of shares and votes in Xspray

Xspray Pharma AB (Nasdaq Stockholm: XSPRAY) announces today that the number of shares and votes in Xspray Pharma has changed as a result of shares being registered due to the directed share issue which was carried out in October 2020.

Through the direct share issue, carried out in October 2020, the number of outstanding shares and votes has increased by 1,861,291, from 17,031,213 to 18,892,504. The share capital has increased by SEK 1,861,291 from SEK 17,031,213 to SEK 18,892,504.

For further information, please contact:

Per Andersson, CEO, Xspray Pharma AB Phone: +46 (0) 706 88 23 48 E-mail: [email protected]

About Xspray Pharma

Xspray Pharma AB (publ) is a product development company with multiple product candidates in clinical development. Xspray uses its innovative, patented RightSize technology to develop improved and generic versions of marketed drugs, primarily protein kinase inhibitors (PKIs) for the treatment of cancer. The segment is the second largest in oncology, and drug prices are very high.

The company´s innovative technology allows Xspray Pharma to gain entry as the first competitor to today's original drugs before the secondary patents expire. Xspray's goal is to become the leader in the development of improved drugs or generic versions of PKIs already marketed for the treatment of cancer, which numbered to 54 in December 2019. The company' s leading product candidates, HyNap-Dasa, HyNap-Sora and HyNap-Nilo, are stable amorphous versions of the three blockbuster cancer drugs Sprycel® (dasatinib), Nexavar® (sorafenib) and Tasigna® (nilotinib), respectively. The launch of the first product candidate, HyNap-Dasa, is planned to take place in 2021. The substance patent for the original drug Sprycel® (dasatinib) expires at the end of 2020, and the secondary patents in 2026, which offers Xspray's HyNap-Dasa a period of five years of semi-exclusivity before other competitors gain access to the market.

The company has patented manufacturing technology, equipment and the resulting products. The shares in Xspray Pharma are traded on Nasdaq Stockholm. www.xspraypharma.com

This information is information that Xspray Pharma AB is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2020- 10-30 14:30 CET.